Top

Published in:

Open Access 01-03-2009 | Research Paper

Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung

Authors: Tatjana M. H. Niers, Lois W. Brüggemann, Clara P. W. Klerk, Femke J. M. Muller, Tessa Buckle, Pieter H. Reitsma, Dick J. Richel, C. Arnold Spek, Olaf Van Tellingen, Cornelis J. F. Van Noorden

Published in: Clinical & Experimental Metastasis | Issue 3/2009

Abstract

Cancer progression is facilitated by blood coagulation. Anticoagulants, such as Hirudin and low molecular weight heparins (LMWHs), reduce metastasis mainly by inhibition of thrombin formation and L- and P-selectin-mediated cell-cell adhesion. It is unknown whether the effects are dependent on cancer cell type. The effects of anticoagulants on tumor development of K1735 and B16 melanoma cells and CT26 colon cancer cells were investigated in mouse lung. Tumor load was determined noninvasively each week up to day 21 in all experiments using bioluminescence imaging. Effects of anticoagulants on tumor development of the three cell lines were correlated with the fibrin/fibrinogen content in the tumors, expression of tissue factor (TF), protease activated receptor (PAR)-1 and -4 and CD24, a ligand of L- and P-selectins. Hirudin inhibited tumor development of B16 cells in lungs completely but did not affect tumor growth of K1735 and CT26 cells. Low molecular weight heparin did not have an effect on K1735 melanoma tumor growth either. TF and PAR-4 expression was similar in the three cell lines. PAR-1 and CD24 were hardly expressed by K1735, whereas CT26 cells expressed low levels and B16 high levels of PAR-1 and CD24. Fibrin content of the tumors was not affected by LMWH. It is concluded that effects of anticoagulants are dependent on cancer cell type and are correlated with their CD24 and PAR-1 expression.

Büller HR, Van Doornmaal FF, Van Sluis GL et al (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 5(suppl 1):246–254. doi:10.1111/j.1538-7836.2007.02497.x PubMedCrossRef

Blom JW, Doggen CJM, Osanto S et al (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 293:715–722. doi:10.1001/jama.293.6.715 CrossRef

Niers TM, Klerk CP, Dinisio M et al (2007) Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol/Hematol 61:195–207. doi:10.1016/j.critrevonc.2006.07.007 CrossRef

Smorenburg SM, Van Noorden CJ (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93–105PubMed

Altinbas M, Coskun HS, Er O et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266–1271. doi:10.1111/j.1538-7836.2004.00871.x PubMedCrossRef

Kakkar AK, Levine MN, Kadziola Z et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944–1948. doi:10.1200/JCO.2004.10.002 PubMedCrossRef

Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130–2135. doi:10.1200/JCO.2005.03.134 PubMedCrossRef

Lebeau B, Chastang C, Brechot JM et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 74:38–45. doi:10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-EPubMedCrossRef

Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. The New Engl J Med 349:146–153. doi:10.1056/NEJMoa025313 CrossRef

10.

Hembrough TA, Swartz GM, Papathanassiu A et al (2003) Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63:2997–3000PubMed

11.

Banke IJ, Arlt MJ, Mueller MM et al (2005) Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost 94:1084–1093PubMed

12.

Hu L, Lee M, Campbell W et al (2004) Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104:2746–2751. doi:10.1182/blood-2004-03-1047 PubMedCrossRef

13.

Palumbo JS, Kombrinck KW, Drew AF et al (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309PubMed

14.

Broze GJ Jr (1995) Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 46:103–112. doi:10.1146/annurev.med.46.1.103 PubMedCrossRef

15.

Brüggemann LW, Versteeg HH, Niers TM et al (2008) Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med (PMID: 18363839)

16.

Klerk CP, Smorenburg SM, Spek CA et al (2007) Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. J Cell Mol Med 11:561–568. doi:10.1111/j.1582-4934.2007.00046.x PubMedCrossRef

17.

Stevenson JL, Choi SH, Varki A (2005) Differential metastasis inhibition by clinically relevant levels of heparins–correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11:7003–7011. doi:10.1158/1078-0432.CCR-05-1131 PubMedCrossRef

18.

Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, Gille J (2006) The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 95:535–540PubMed

19.

Stevenson JL, Varki A, Borsig L (2007) Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 120(suppl 2):S107–S111. doi:10.1016/S0049-3848(07)70138-X PubMedCrossRef

20.

Borsig L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98:3352–3357. doi:10.1073/pnas.061615598 PubMedCrossRef

21.

Chung AW, Jurasz P, Hollenberg MD et al (2002) Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 135:1123–1132. doi:10.1038/sj.bjp.0704559 PubMedCrossRef

22.

Kahn ML, Nakanishi-Matsui M, Shapiro MJ et al (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879–887. doi:10.1172/JCI6042 PubMedCrossRef

23.

Huo Y, Schober A, Forlow SB et al (2003) Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9:61–67. doi:10.1038/nm810 PubMedCrossRef

24.

Bastida E, Escolar G, Ordinas A et al (1986) Morphometric evaluation of thrombogenesis by microvesicles from human tumor cell lines with thrombin-dependent (U87MG) and adenosine diphosphate-dependent (SKNMC) platelet-activating mechanisms. J Lab Clin Med 108:622–627PubMed

25.

Esumi N, Todo S, Imashuku S (1987) Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line. Cancer Res 47:2129–2135PubMed

26.

Heinmoller E, Schropp T, Kisker O et al (1995) Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol 30:1008–1016. doi:10.3109/00365529509096346 PubMedCrossRef

27.

Collen A, Smorenburg SM, Peters E et al (2000) Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60:6196–6200PubMed

28.

Dvorak HF, Senger DR, Dvorak AM (1983) Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastas Rev 2:41–73. doi:10.1007/BF00046905 CrossRef

29.

Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893–895. doi:10.1126/science.887927 PubMedCrossRef

30.

Klerk CP, Overmeer RM, Niers TM et al (2007) Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. BioTechniques 43(Suppl):7–13. doi:10.2144/000112515

31.

Kemper EM, Leenders W, Kusters B et al (2006) Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 42:3294–3303. doi:10.1016/j.ejca.2006.07.013 PubMedCrossRef

32.

Niemetz J (1972) Coagulant activity of leukocytes. Tissue factor activity. J Clin Invest 51:307–313. doi:10.1172/JCI106815 PubMedCrossRef

33.

Even-Ram S, Uziely B, Cohen P et al (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4:909–914. doi:10.1038/nm0898-909 PubMedCrossRef

34.

Massi D, Naldini A, Ardinghi C et al (2005) Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 36:676–685. doi:10.1016/j.humpath.2005.04.008 PubMedCrossRef

35.

Yin YJ, Salah Z, Grisaru-Granovsky S et al (2003) Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 23:940–944. doi:10.1161/01.ATV.0000066878.27340.22 PubMedCrossRef

36.

Nierodzik ML, Plotkin A, Kajumo F et al (1991) Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 87:229–236. doi:10.1172/JCI114976 PubMedCrossRef

37.

Nierodzik ML, Kajumo F, Karpatkin S (1992) Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52:3267–3272PubMed

38.

Wojtukiewicz MZ, Tang DG, Nelson KK et al (1992) Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 68:233–245. doi:10.1016/0049-3848(92)90081-K PubMedCrossRef

39.

Klepfish A, Greco MA, Karpatkin S (1993) Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 53:978–982PubMedCrossRef

40.

Black PC, Mize GJ, Karlin P et al (2007) Overexpression of protease-activated receptors-1,-2, and -4 (PAR-1, -2, and -4) in prostate cancer. Prostate 67:743–756. doi:10.1002/pros.20503 PubMedCrossRef

41.

Kim YJ, Borsig L, Varki NM et al (1998) P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 95:9325–9330. doi:10.1073/pnas.95.16.9325 PubMedCrossRef

42.

Ludwig RJ, Boehme B, Podda M et al (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64:2743–2750. doi:10.1158/0008-5472.CAN-03-1054 PubMedCrossRef

43.

Koenig A, Norgard-Sumnicht K, Linhardt R et al (1998) Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 101:877–889. doi:10.1172/JCI1509 PubMedCrossRef

44.

Nelson RM, Cecconi O, Roberts WG et al (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253–3258PubMed

45.

Mook OR, Van Marle J, Vreeling-Sindelarova H et al (2003) Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology 38:295–304. doi:10.1053/jhep.2003.50297 PubMedCrossRef

Title: Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung
Authors: Tatjana M. H. Niers
Lois W. Brüggemann
Clara P. W. Klerk
Femke J. M. Muller
Tessa Buckle
Pieter H. Reitsma
Dick J. Richel
C. Arnold Spek
Olaf Van Tellingen
Cornelis J. F. Van Noorden
Publication date: 01-03-2009
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 3/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9227-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

The CXCR4/CXCL12 axis in endometrial cancer

A gene expression signature that defines breast cancer metastases

BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-κB binding site of the uPA promoter

Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells

Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP

Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer